-
Mashup Score: 34Averting a terminal transplant cascade - 1 month(s) ago
In this issue of Blood, Jodele et al demonstrate that using C5 complement inhibitor, eculizumab, is associated with high survival rates in children and young ad
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 14Aging Kairos: treating older Hodgkin patients - 1 month(s) ago
In this issue of Blood, Ghesquières et al1 conclude that the prednisone, vinblastine, doxorubicin, and bendamustine (PVAB) regimen, which lacks any novel drugs,
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 82Old is gold: frontline etoposide for pHLH - 2 month(s) ago
In this issue of Blood, Böhm et al1 provide contemporary real-world data on the use of etoposide for frontline therapy for pediatric patients with primary hemop
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 35Higher hemoglobin is better in thalassemia - 2 month(s) ago
In this issue of Blood, Musallam, Forni, and colleagues show that survival in transfusion dependent β-thalassemia (TDT) is measurably better in patients whose p
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 76Old is gold: frontline etoposide for pHLH - 2 month(s) ago
In this issue of Blood, Böhm et al1 provide contemporary real-world data on the use of etoposide for frontline therapy for pediatric patients with primary hemop
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 66Toward a cure for cHL without chemotherapy - 2 month(s) ago
In this issue of Blood, Friedberg and colleagues present important long-term follow-up from a clinical trial of combinations based on brentuximab vedotin (BV) f
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 66Toward a cure for cHL without chemotherapy - 2 month(s) ago
In this issue of Blood, Friedberg and colleagues present important long-term follow-up from a clinical trial of combinations based on brentuximab vedotin (BV) f
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 2A phase 2 study of the PI3Kδ inhibitor parsaclisib in relapsed and refractory marginal zone lymphoma (CITADEL-204) - 2 month(s) ago
Parsaclisib, a highly selective, potent PI3Kδ inhibitor, demonstrated durable responses and an overall manageable safety profile in R/R MZL.Investigation is nee
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 9A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia - 2 month(s) ago
Low-intensity chemotherapy plus venetoclax was safe and active in heavily pretreated relapsed/refractory ALL.The CR/CRi rate of 57% compares favorably with hist
Source: ashpublications.orgCategories: General Medicine News, Onc News and JournalsTweet
-
Mashup Score: 37Does BTKi improve CAR T-cell therapy in MCL? - 2 month(s) ago
In this issue of Blood, Minson et al present the first clinical study investigating the combinatorial use of a Bruton tyrosine kinase inhibitor (BTKi) with CD19
Source: ashpublications.orgCategories: General Medicine News, Rare DiseaseTweet
Averting a terminal transplant cascade https://t.co/2rRkR8zSJb #clinicaltrialsandobservations https://t.co/EGooalrEzk